Innovative Solution for Reducing Oxygen Diffusion

Schreiner MediPharm Presents Novel Labels with Gas Barrier Function at Pharmapack 2024

Schreiner MediPharm, a leading supplier of innovative packaging solutions for the pharmaceutical industry, is going to present its new functional labels for reducing oxygen diffusion on COC syringes for the first time at Pharmapack. The international trade fair for the pharmaceutical industry will take place in Paris from January 24 to 25. Schreiner MediPharm will be showcasing its latest product developments there at booth no. D78.

Prefilled polymer COC syringes have established themselves as an alternative to glass syringes in the pharmaceutical industry. They offer advantages such as break resistance, lower weight, greater design flexibility, and less protein absorption compared to glass containers. However, they have reduced oxygen and gas barrier properties which poses a challenge particularly in the case of oxygen-sensitive biologics and biosimilars that are used for treating cancer or autoimmune diseases.

The new labels with a barrier function from Schreiner MediPharm offer an innovative and efficient solution for mastering this challenge. Thanks to their special material selection and design, these functional labels can significantly reduce oxygen diffusion in COC syringes. Customers can choose between two variants: a Gas-Protect-Label covering the syringe barrel as much as possible and a Syringe-Closure-Wrap with an additional barrier function that wraps around the syringe barrel and the cap like a second skin and is sealed at the upper end. Due to its integrated first-opening indication, Syringe-Closure-Wrap additionally offers reliable tamper evidence.

Both label variants have been extensively tested on SCHOTT TOPPAC® 1 ml long COC syringes in terms of their barrier properties and achieved impressive results: oxygen ingress is significantly reduced. Schreiner MediPharm develops the labels with a gas barrier function as customized products for the specific application and the active pharmaceutical ingredient (API) contained in the syringe to ensure the best possible protective function. The labels enable pharmaceutical manufacturers to easily implement an oxygen barrier without adjustments to the primary packaging or complex process changes.

“Thanks to our functional labels with a barrier function, sensitive APIs in COC syringes can be reliably protected against gas diffusion without requiring major capital expenditures. Our solution is a cost-efficient and flexible response to the challenges of the pharmaceutical industry,” says Stefan Wiedemann, Senior Director Strategic Marketing and Business Development at Schreiner MediPharm.

Press Images

Publication free of charge if named © Schreiner MediPharm

SMP_Presse_Gas-Protection-Labels.jpg
The labels with gas barrier function can significantly reduce oxygen diffusion in COC syringes.

Download (Format: jpg, 369 KB)

Communiqué de presse au format Word

Download (Format: docx, 64 KB)

About Schreiner MediPharm

Schreiner MediPharm, a business unit of Schreiner Group GmbH & Co. KG based in Oberschleissheim near Munich, is a leading developer and manufacturer of innovative, multifunctional specialty labels and marking solutions with value-added benefits for the healthcare industry. Thanks to its strong solutions expertise and specialized know-how Schreiner MediPharm is a highly capable development partner and reliable quality supplier to leading pharmaceutical and medical device technology companies worldwide.

Your contact person for queries

Bernd Pfadler
Product Communications

Phone +49 89 31584 5494

Contact via e-mail

About SCHOTT Pharma

SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 821 million in the fiscal year 2022.